Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Universal Ibogaine Inc IBOGF


Primary Symbol: V.IBO

Universal Ibogaine Inc. is a Canada-based life sciences company. The Company is transforming addiction treatment using medicalized ibogaine through a planned Canadian clinical trial focused on opioid use disorders. The Company is engaged in developing a holistic addiction treatment protocol at its Kelburn Recovery Center (located near Winnipeg, Manitoba), which paired with the planned ibogaine detox protocol, is intended to treat addiction and improve the lives of individuals and families affected by addiction. Ibogaine is a naturally occurring molecule derived from the root bark of the iboga tree and other plants. It is a potent and serious medical psychedelic which has addiction interrupting properties. Ibogaine targets multiple receptors across multiple sites in the brain and metabolizes into noribogaine, a serotonin re-uptake inhibitor that remains in the body for 1-4 months, associated with elimination of addictive cravings.


TSXV:IBO - Post by User

Post by yukon_goldon Sep 23, 2022 8:23am
249 Views
Post# 34981188

Universal Ibogaine Announces Kelburn Reopening Date

Universal Ibogaine Announces Kelburn Reopening Date

Universal Ibogaine says Kelburn addiction recovery clinic to reopen on October 17, 2022

 
"We have a large referral network for clients, and the situation with the addiction and opioid crisis is still only getting worse by the day so we will likely be full pretty quickly," said the company's chief clinics officer Dr Ian Rabb.

September 22, 2022 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, advises that it’s research and development clinic, the Kelburn Mental Health and Addiction Recovery Center is scheduled to reopen and commence business operations on October 17, 2022 .

Dr Ian Rabb, Universal Ibogaine Chief Clinics Officer stated: “progress is going remarkably well on the renovations and program development, we have key hires in place, and we are excited to open and start helping people again. We are looking at about 50% of our expanded occupancy when we open the doors again in October as of today.  We have a large referral network for clients and the situation with the addiction and opioid crisis is still only getting worse by the day so we will likely be full pretty quickly.  We are also quite pleased with the progress we are making on the ibogaine clinical trial process.  We will be the first legal ibogaine clinic in Canada.  This could be the turning point in the opioid crisis.”

About Universal Ibogaine Inc.

UI is a life sciences company, with a mission to transform addiction treatment using medicalized ibogaine through a planned Canadian clinical trial focused on opioid use disorder, and ultimately to utilize that protocol globally through planned future licensing agreements.   UI is concurrently developing a state of the art holistic addiction treatment protocol at its Kelburn Recovery Centre that, which when paired with the planned ibogaine detox protocol, is intended to revolutionize the way we treat addiction and drastically improve the lives of individuals and families affected by addiction.

For further information: 

Investor Relations: Dugan Selkirk, IR Manager

dugan.selkirk@universalibogaine.com

Related Links

https://universalibogaine.com 

<< Previous
Bullboard Posts
Next >>